Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses phase 3 clinical trials of atezolizumab, an anti-PD-L1 monoclonal antibody, compared with standard chemotherapy in PD-L1-selected chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC).